Biomedical Occupation or Discipline – Page 2

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

3 weeks ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

3 weeks ago talkbio0Tagged biotech partnership, cardiometabolic diseases, Collaboration, Deep Apple, G-Protein-Coupled Receptors, Nordisk, Obesity, Oral Medicine, R&D, small molecule therapeutics, Target

Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership

Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

4 weeks ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, biotech collaboration, Drug Development, Drug Discovery, Eli, Eli Lilly, muscle health, Muscle-Boosting Drugs, Obesity, stem cell-secreted proteins

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

4 weeks ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

All innuendo and conspiracy: RFK Jr.’s vaccine advisory overhaul undermines vaccine confidence, experts say

4 weeks ago talkbio0Tagged ACIP, advisory, conspiracy, overhaul, public health medicine (field), RFK Jr., Self Confidence, Vaccines

RFK Jr.; vaccine advisory; ACIP; public health; conspiracy; confidence; overhaul

23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron

4 weeks ago talkbio0Tagged Anne Wojcicki, asset, auction, Bankruptcy, Regeneron, Sales - occupational activity, Science of genetics, TTAM

23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

1 month ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

1 month ago talkbio0Tagged biotech collaboration, Camurus, cardiometabolic health, Drug Development, eli lilly, FluidCrystal technology, incretin drugs, long-acting therapies, Obesity, pharma partnerships

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration

BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback

1 month ago talkbio0Tagged Agonist, APJ, BioAge, Exercise, incretin therapy, Metabolic Diseases, mimetics, nanobody, Obesity, small molecule agonists

BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus

1 month ago talkbio0Tagged Acquisition, Ayvakit, Biopharma, Blueprint Medicines, elenestinib, Immunology, Infrequent, Mastocytosis, Systemic, pipeline, sanofi

Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline